LP230004-6

GlycA

Active

Description

GlycA was first seen as a signal on a nuclear magnetic resonance spectrum for lipoprotein particle analysis. GlycA was found to emanate from a subset of glycan N-acetylglucosamine residues on enzymatically glycosylated acute phase proteins. That signal was thought possible to provide an advantageous marker for systemic inflammation. The additional acute phase proteins included in the signal are alpha-1-acid glycoprotein, haptoglobin, alpha-1-antitrypsin, alpha-1-antichymotrypsin and transferrin. GlycA biomarker levels correlates with high-sensitivity C-reactive protein, fibrinogen and interleukin-6. GlycA has notable analytical and clinical attributes that may supplement or improve upon current systemic inflammatory markers including for rheumatoid arthritis. PMID: 25779987(https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-015-0646-x) GlycA improves the risk prediction of patients with severe cardiovascular disease.( http://content.onlinejacc.org/article.aspx?articleid=2197811) Source: Regenstrief LOINC

Basic Part Properties

Part Name

GlycA

Part Display Name

GlycA

Part Type

Component (Describes the core component or analyte measured)

Created On

2016-09-15

Construct for LOINC Short Name

GlycA

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP230004-6

Language Variants Get Info

LOINC Copyright

Copyright © 2025 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.